Our organs-on-chip research has generated two successful spin-off companies, demonstrating our commitment to translating academic innovation into commercial solutions for preclinical drug testing and oncology research services.
(founded in 2015)
AlveoliX commercializes our breathing lung-on-chip technology,, offering pharmaceutical companies advanced in vitro platforms for respiratory disease modeling, drug efficacy testing, and inhalation toxicology studies.
(founded in 2026)
Vitronco is a contract research organization offering vascularized tumor-on-chip services for oncology drug development, enabling more physiologically relevant cancer research and therapeutic screening.
